Tarsus Pharmaceuticals Reports First Quarter 2025 Sales Growth

Published on May 7, 2025
IRVINE, Calif.—Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a biopharmaceutical company focused on the development and commercialization of therapeutic eyecare treatments, has announced financial results for the first quarter ended March 31, 2025. Net product sales were reported at $78.3 million compared with $24.7 million for the same period in 2024, driven by approximately 72,000 bottles of Xdemvy delivered to patients compared with approximately 26,000 bottles delivered in the prior year period. Xdemvy (lotilaner ophthalmic solution) 0.25% is a novel prescription eye drop designed to treat Demodex blepharitis, a condition caused by an overpopulation of Demodex microscopic mites that live in eyelash follicles and meibomian glands. It was approved by the FDA in July of 2023, as reported in VMAIL.
Continue reading on website
Other news

CIME 2025: Kristin Barnes, OD, on early detection and effective treatment of Demodex blepharitis

May 6, 2025
The leading source of breaking news, news analysis, and emerging research reports in optometry, Optometry Times® disseminates practical content by optometrists for optometrists that can be immediately applied to improve the clinical experience.

ARVO 2025: Head-scanning training program improves blind-side detection during virtual driving for hemianopia patients

May 7, 2025
Investigators also reported that the benefits of the training for patients with hemianopia, driven by improved blind-side scanning, lasted for more than a month.